Harrow Highlights IHEEZO and BYOOVIZ Data at ASRS, but Leverage and Regulatory Risks Remain

What happened

Harrow presented three studies at the ASRS 2026 Annual Meeting, expanding clinical evidence for IHEEZO and BYOOVIZ. While these data may bolster physician confidence, the company's fundamental financial strain persists. Net losses and high interest costs continue to burden results, with net debt/EBITDA at 8.21x and interest coverage of just 0.58x. Regulatory overhang from the New Jersey outsourcing facility remains a significant risk that could impair cash generation. With a rich valuation and no durable free cash flow, the positive news does little to alter the underlying risk/reward.

Implication

Harrow's ASRS presentations support the clinical profile of IHEEZO and BYOOVIZ, potentially aiding adoption, but this does not address the company's core financial risks. Persistent net losses, a debt load of $250M at 8.625%, and interest coverage below 1x leave little margin for error. Regulatory scrutiny of the NJ compounding facility could trigger a consent decree, materially impairing operations. The market cap of ~$1.4B prices in substantial future growth, yet the company has not demonstrated sustainable free cash flow. Investors should not confuse positive headlines with a fix for the balance sheet; the thesis remains fragile.

Thesis delta

This news does not shift the underlying thesis. Harrow's financial leverage and regulatory overhang dominate, and the incremental clinical data are unlikely to drive a material improvement in cash flow or de-leveraging. The core risks—net losses, high interest costs, and potential FDA enforcement—remain unchanged, reinforcing the bearish stance.